Silence Therapeutics (STU:XRP2) FFO


STU:XRP2 Silence Therapeutics PLC STU:XRP2
46 GF Score
Price €9.20
GF Value €0.31
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:XRP2
46GF Score
Silence Therapeutics PLC STU:XRP2
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Silence Therapeutics (STU:XRP2) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of €9.20 is trading 2867.7% above its estimated GF Value™ of €0.31. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:XRP2:

  • FFO:
  • GF Value™: €0.31 vs. price of €9.20 (2867.7% above fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the STU:XRP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Silence Therapeutics Business Description

Other Exchanges SLN:USASLNCF:USA
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
46GF Score

Get the complete analysis for STU:XRP2

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.20
Price
€0.31
GF Value